An estimated 22,000 new cases of ovarian cancer are diagnosed in the United States each year, and mortality rates are high if the disease is not caught and treated early.
Members of the clinical community have attempted to identify modifiable … Read more
Niraparib (Zejula, Tesaro) has been approved by the US Food and Drug Administration (FDA) for use in the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial … Read more
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin (PLD) failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. There was a survival advantage, however, specifically in patients who … Read more
Maintenance treatment with olaparib (Lynparza, AstraZeneca) can significantly extend progression-free survival (PFS) in a subset of patients with ovarian cancer.
The results of a phase 3 trial showed that in patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian … Read more
Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy, according to a study presented at the 2017 Society of Gynecologic Oncology Annual Meeting.1
An important aspect of shared decision-making is patient preference … Read more
Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.
Results showed a median PFS of … Read more
By: Annette McElhiney
As a retired college professor, I firmly believe that knowledge is power and may also result in a longer healthier life. In a recent Wall Street Journal article, “How to Get Patients to Take More Control … Read more
Screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the 1 year after screening ended, a multicenter study showed.
Algorithm-based screening with an assay for the CA-125 cancer antigen plus transvaginal … Read more
Defects in a key gene—long thought to drive cancer by turning off the protection afforded by the BRCA genes—spur cancer growth on their own, according to a study led by researchers from NYU Langone Medical Center (Oncotarget 2017; doi: … Read more
Using a new insight into the nature of ovarian cancer, a team of UC San Diego scientists have found potential new drug targets.
The researchers discovered that existing drugs targeting autophagy were effective in drug-resistant human tumors grafted onto mice, … Read more
Women who have a strong family history of breast or ovarian cancer are more likely to be affected by cancer of the ovaries, fallopian tube, or peritoneal cavity. This is thought to be due to a mutation in one of … Read more
By: Annette McElhiney
What lies ahead this year for health care and cancer care? I’m not a medical doctor, I’m just an 8½-year ovarian cancer survivor in remission. Who knows, the disease could come back 20 years later. So how … Read more
Ovarian cancer remains the most deadly gynecologic malignancy in the United States with more than 14,000 deaths in 2016. Yet, the prevalence remains low with approximately 22,000 cases in 2016. Stage at diagnosis is one of the strongest predictors of … Read more
Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings in the … Read more
Results from the Gynecologic Oncology Group (GOG) 252 trial, while highly anticipated in the oncology community, did not give any additional clarity for the use of intravenous (IV) versus intraperitoneal (IP) chemotherapy for patients with ovarian cancer, says Franco M. … Read more
Today in celebration of its 25th anniversary, the Foundation for Women’s Cancer with the Society of Gynecologic Oncology released a comprehensive report on the most recent advances in the detection and treatment of gynecologic cancers.
The 2016 State of the … Read more
Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more
As we step into 2017, a big question looming in the minds of all stakeholders in the cancer research arena is: What is the future of cancer research in the new administration? Members of Congress on both sides of the … Read more
Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, a cancer doctor at the UNM Comprehensive Cancer Center, hopes a new therapy that delivers a one-two punch to cancer cells will … Read more
By: Annette McElhiney
Many of you have already read Dr. Maurie Markman’s article “In Ovarian Cancer Advancements, Finding New Biomarkers is Key” posted in the Clearity blog. It provoked me as an ovarian cancer survivor and non-medical professional … Read more
